Zeidan A, Al‐Kali A, Borate U, Cluzeau T, DeZern A, Esteve J, Giagounidis A, Kobata K, Lyons R, Platzbecker U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry‐Boulot C, Sadek I, Ma F, Iordan A, Sabo J, Garcia‐Manero G. P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO‐MYELOID CLINICAL TRIAL PROGRAM. HemaSphere 2022, 6: 682-683. DOI: 10.1097/01.hs9.0000846032.37876.c9.Peer-Reviewed Original Research